Subscribe
shutterstock_521453077_rolandmagnusson
Roland Magnusson / Shutterstock.com
17 August 2020Big PharmaSarah Morgan

EU reaches first COVID-19 vaccine deal

The European Commission reached its first agreement to supply EU member states with an experimental COVID-19 vaccine with  AstraZeneca late last week.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
EU concludes COVID-19 vaccine talks with Pfizer
10 September 2020   The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.
Americas
PureShield sues over COVID-19 disinfectant
30 September 2020   Antimicrobial company PureShield has accused its competitor Allied BioScience of infringing ten patents through the sale of a surface disinfectant, which claims protection against COVID-19 for up to seven days.
Americas
Milestone COVID-19 vaccine offers 90% protection
10 November 2020   A coronavirus vaccine unveiled by pharmaceutical companies Pfizer and BioNTech can potentially prevent more than 90% of people from getting COVID-19, it has been announced.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
EU concludes COVID-19 vaccine talks with Pfizer
10 September 2020   The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.
Americas
PureShield sues over COVID-19 disinfectant
30 September 2020   Antimicrobial company PureShield has accused its competitor Allied BioScience of infringing ten patents through the sale of a surface disinfectant, which claims protection against COVID-19 for up to seven days.
Americas
Milestone COVID-19 vaccine offers 90% protection
10 November 2020   A coronavirus vaccine unveiled by pharmaceutical companies Pfizer and BioNTech can potentially prevent more than 90% of people from getting COVID-19, it has been announced.

More on this story

Big Pharma
EU concludes COVID-19 vaccine talks with Pfizer
10 September 2020   The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.
Americas
PureShield sues over COVID-19 disinfectant
30 September 2020   Antimicrobial company PureShield has accused its competitor Allied BioScience of infringing ten patents through the sale of a surface disinfectant, which claims protection against COVID-19 for up to seven days.
Americas
Milestone COVID-19 vaccine offers 90% protection
10 November 2020   A coronavirus vaccine unveiled by pharmaceutical companies Pfizer and BioNTech can potentially prevent more than 90% of people from getting COVID-19, it has been announced.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York